New members of Medivir’s management group

Stockholm, Sweden — Medivir AB (OMX: MVIR) is, as previously announced,
conducting a reorganisation of the company’s management group which will, as of
1 March, comprise six people, including the President & CEO. Medivir has
recruited two new people in order to strengthen important functions and generate
an increased operational focus.

Christine Lind has been employed as the Executive Vice President, Strategic
Business Development. She will have operational responsibility for the newly
created Strategic Business Development function. Christine’s most recent
position was as Vice President, Business Development at LifeCell Corporation in
New York, and she also has twelve years of investment banking experience at
Merrill Lynch & Co. and Gerard Klauer Mattison & Co. Christine studied Finance
and Information Systems at New York University and also has a Master of Business
Administration from Columbia Business School.

Ola Burmark has been employed as the Chief Financial Officer. His areas of
responsibility include not only operational responsibility for the Finance &
Administration function, but also responsibility for Investor Relations. Ola’s
previous positions include that of CFO at OneMed AB and Aditro Holding AB. He
has also worked as SVP Finance and M&A at Thule Group AB and Cell Network AB, as
Cash Manager at AB SCA Finans, and as an auditor at Ernst & Young. Ola has a
B.Sc. in Finance and Business Administration.

“I’m delighted to welcome Christine and Ola to Medivir. They both bring
extensive experience and specialist skills that will be of huge benefit to us,
now that we are accelerating our work on strategic implementation and long-term
value generation within the company. I look forward to continuing this work in
partnership with the new management group and other members of staff,” says
Niklas Prager, President & CEO of Medivir AB.

For more information please contact:
Niklas Prager, CEO Medivir AB, phone +46 (0)8-407 64 30.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on
infectious diseases and oncology. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a growing portfolio of specialty care
pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm
Mid Cap List.